Addition Therapeutics emerged from stealth today, announcing $100 million in financing to date and notable progress advancing its mission to fulfill the transformative promise of genomic medicine for people impacted by both chronic and rare diseases. Addition's investor syndicate includes SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC.